Latest news
FDA panel to review Grail's blood-based cancer test - FirstWord PHARMAFirstWord PHARMA · Fri, 07 Aug 2026 21:32:11 GMTGRAIL to face FDA AdCom for Galleri cancer test (GRAL:NASDAQ) - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 15:43:36 GMTFDA panel to review GRAIL’s cancer detection test on Sept. 23 - Investing.com CanadaInvesting.com Canada · Fri, 07 Aug 2026 15:13:16 GMTGRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - PR NewswirePR Newswire · Fri, 07 Aug 2026 15:05:00 GMTGRAIL Bets Its Galleri Panel Will Set The FDA Bar For Future MCEDs - insights.citeline.cominsights.citeline.com · Fri, 07 Aug 2026 12:26:38 GMTSpectral Medical (EDT) Announces Q2 2026 Financials and FDA Advances PMX PMA Review - Kalkine MediaKalkine Media · Fri, 07 Aug 2026 11:30:00 GMTArtivion Inc (AORT) (Q2 2026) Earnings Call Highlights: PMA Approval and Endospan Acquisition ... - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 05:11:30 GMTAORT: Q2 revenue and EBITDA grew strongly, with AMDS PMA approval and NEXUS acquisition fueling outlook - TradingViewTradingView · Thu, 06 Aug 2026 22:01:04 GMT